keyword
Keywords Patient derived tissue slice c...

Patient derived tissue slice culture treatment

https://read.qxmd.com/read/38559899/enhanced-articular-cartilage-regeneration-using-costal-chondrocyte-derived-scaffold-free-tissue-engineered-constructs-with-ascorbic-acid-treatment
#1
JOURNAL ARTICLE
Kaiwen Zheng, Yiyang Ma, Cheng Chiu, Mengxin Xue, Changqing Zhang, Dajiang Du
BACKGROUND: Cartilage tissue engineering faces challenges related to the use of scaffolds and limited seed cells. This study aims to propose a cost-effective and straightforward approach using costal chondrocytes (CCs) as an alternative cell source to overcome these challenges, eliminating the need for special culture equipment or scaffolds. METHODS: CCs were cultured at a high cell density with and without ascorbic acid treatment, serving as the experimental and control groups, respectively...
March 2024: Journal of Orthopaedic Translation
https://read.qxmd.com/read/38317193/targeting-of-h19-cell-adhesion-molecules-circuitry-by-gsk-j4-epidrug-inhibits-metastatic-progression-in-prostate-cancer
#2
JOURNAL ARTICLE
Valeria Pecci, Fabiola Troisi, Aurora Aiello, Sara De Martino, Angela Carlino, Vincenzo Fiorentino, Cristian Ripoli, Dante Rotili, Francesco Pierconti, Maurizio Martini, Manuela Porru, Francesco Pinto, Antonello Mai, Pier Francesco Bassi, Claudio Grassi, Carlo Gaetano, Alfredo Pontecorvi, Lidia Strigari, Antonella Farsetti, Simona Nanni
BACKGROUND: About 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression...
February 5, 2024: Cancer Cell International
https://read.qxmd.com/read/38271182/invasive-growth-of-brain-metastases-is-linked-to-chi3l1-release-from-pstat3-positive-astrocytes
#3
JOURNAL ARTICLE
Matthew Dankner, Sarah M Maritan, Neibla Priego, Georgia Kruck, Andriniaina Nkili-Meyong, Javad Nadaf, Rebecca Zhuang, Matthew G Annis, Dongmei Zuo, Alexander Nowakowski, Marco Biondini, Alexander Kiepas, Caitlyn Mourcos, Phuong Le, Francois Charron, Yanis Inglebert, Paul Savage, Louis Théret, Marie-Christine Guiot, R Anne McKinney, William J Muller, Morag Park, Manuel Valiente, Kevin Petrecca, Peter M Siegel
BACKGROUND: Compared to minimally invasive brain metastases (MI BrM), highly invasive (HI) lesions form abundant contacts with cells in the peritumoral brain parenchyma and are associated with poor prognosis. Reactive astrocytes (RAs) labeled by phosphorylated STAT3 (pSTAT3) have recently emerged as a promising therapeutic target for BrM. Here, we explore whether BrM invasion pattern is influenced by pSTAT3+ RAs and may serve as a predictive biomarker for STAT3 inhibition. METHODS: We used immunohistochemistry to identify pSTAT3+ RAs in HI and MI human and patient-derived xenograft (PDX) BrM...
January 25, 2024: Neuro-oncology
https://read.qxmd.com/read/38067230/exploring-the-in-vitro-and-in-vivo-therapeutic-potential-of-braf-and-mek-inhibitor-combination-in-nras-mutated-melanoma
#4
JOURNAL ARTICLE
Heike Niessner, Anna Hüsch, Corinna Kosnopfel, Matthias Meinhardt, Dana Westphal, Friedegund Meier, Bastian Schilling, Tobias Sinnberg
INTRODUCTION: Patients with NRAS-mutant metastatic melanoma often have an aggressive disease requiring a fast-acting, effective therapy. The MEK inhibitor binimetinib shows an overall response rate of 15% in patients with NRAS-mutant melanoma, providing a backbone for combination strategies. Our previous studies demonstrated that in NRAS-mutant melanoma, the antitumor activity of the MEK inhibitor binimetinib was significantly potentiated by the BRAFV600E/K inhibitor encorafenib through the induction of ER stress, leading to melanoma cell death by apoptotic mechanisms...
November 22, 2023: Cancers
https://read.qxmd.com/read/37806285/patient-derived-precision-cut-tissue-slices-from-primary-liver-cancer-as-a-potential-platform-for-preclinical-drug-testing
#5
JOURNAL ARTICLE
Ravi Jagatia, Ewald J Doornebal, Una Rastovic, Nicola Harris, Moyosoreoluwa Feyide, Anabel Martinez Lyons, Rosa Miquel, Yoh Zen, Ane Zamalloa, Farooq Malik, Andreas Prachalias, Krishna Menon, Luke Boulter, Simon Eaton, Nigel Heaton, Sandra Phillips, Shilpa Chokshi, Elena Palma
BACKGROUND: The exploitation of anti-tumour immunity, harnessed through immunomodulatory therapies, has fundamentally changed the treatment of primary liver cancer (PLC). However, this has posed significant challenges in preclinical research. Novel immunologically relevant models for PLC are urgently required to improve the translation from bench to bedside and back, explore and predict effective combinatorial therapies, aid novel drug discovery and develop personalised treatment modalities...
October 6, 2023: EBioMedicine
https://read.qxmd.com/read/37736770/a-new-scaffold-free-tumoroid-model-provides-a-robust-preclinical-tool-to-investigate-invasion-and-drug-response-in-renal-cell-carcinoma
#6
JOURNAL ARTICLE
Irinka Séraudie, Catherine Pillet, Beatrice Cesana, Pauline Bazelle, Florian Jeanneret, Bertrand Evrard, Frédéric Chalmel, Assilah Bouzit, Christophe Battail, Jean-Alexandre Long, Jean Luc Descotes, Claude Cochet, Odile Filhol
Clear cell Renal Cell Carcinoma (ccRCC) is one of the most prevalent kidney cancers, which is often asymptomatic and thus discovered at a metastatic state (mRCC). mRCC are highly heterogeneous tumors composed of subclonal populations that lead to poor treatment response rate. Several recent works explored the potential of ccRCC tumoroids culture derived from patients. However, these models were produced following a scaffold-based method using collagen I or Matrigel that exhibit lot variability and whose complexity could induce treatment response modifications and phenotypic alterations...
September 22, 2023: Cell Death & Disease
https://read.qxmd.com/read/37495250/innovative-three-dimensional-models-for-understanding-mechanisms-underlying-lung-diseases-powerful-tools-for-translational-research
#7
REVIEW
Mehmet Nizamoglu, Mugdha M Joglekar, Catarina R Almeida, Anna-Karin Larsson Callerfelt, Isabelle Dupin, Olivier T Guenat, Pauline Henrot, Lisette van Os, Jorge Otero, Linda Elowsson, Ramon Farre, Janette K Burgess
Chronic lung diseases result from alteration and/or destruction of lung tissue, inevitably causing decreased breathing capacity and quality of life for patients. While animal models have paved the way for our understanding of pathobiology and the development of therapeutic strategies for disease management, their translational capacity is limited. There is, therefore, a well-recognised need for innovative in vitro models to reflect chronic lung diseases, which will facilitate mechanism investigation and the advancement of new treatment strategies...
September 30, 2023: European Respiratory Review: An Official Journal of the European Respiratory Society
https://read.qxmd.com/read/37192626/a-living-ex%C3%A2-vivo-platform-for-functional-personalized-brain-cancer-diagnosis
#8
JOURNAL ARTICLE
Breanna Mann, Xiaopei Zhang, Noah Bell, Adebimpe Adefolaju, Morrent Thang, Rajaneekar Dasari, Krishna Kanchi, Alain Valdivia, Yang Yang, Andrew Buckley, Vivien Lettry, Carolyn Quinsey, Yasmeen Rauf, David Kram, Noah Cassidy, Cyrus Vaziri, David L Corcoran, Stephen Rego, Yuchao Jiang, Lee M Graves, Denise Dunn, Scott Floyd, Albert Baldwin, Shawn Hingtgen, Andrew B Satterlee
Functional precision medicine platforms are emerging as promising strategies to improve pre-clinical drug testing and guide clinical decisions. We have developed an organotypic brain slice culture (OBSC)-based platform and multi-parametric algorithm that enable rapid engraftment, treatment, and analysis of uncultured patient brain tumor tissue and patient-derived cell lines. The platform has supported engraftment of every patient tumor tested to this point: high- and low-grade adult and pediatric tumor tissue rapidly establishes on OBSCs among endogenous astrocytes and microglia while maintaining the tumor's original DNA profile...
May 8, 2023: Cell reports medicine
https://read.qxmd.com/read/36671030/exploration-of-patient-derived-pancreatic-ductal-adenocarcinoma-ex-vivo-tissue-for-treatment-response
#9
JOURNAL ARTICLE
Tímea Szekerczés, Arun Kumar Selvam, Carlos Fernández Moro, Soledad Pouso Elduayen, Joakim Dillner, Mikael Björnstedt, Mehran Ghaderi
Patient-derived tissue culture models are valuable tools to investigate drug effects and targeted treatment approaches. Resected tumor slices cultured ex vivo have recently gained interest in precision medicine, since they reflect the complex microenvironment of cancer tissue. In this study, we examined the treatment response to an internally developed ex vivo tissue culture model from pancreatic ductal adenocarcinoma (PDAC) and in vitro analysis. Seven PDAC tissues were cultured and subsequently treated with indole-3-pyruvic acid (IPA)...
January 11, 2023: Antioxidants (Basel, Switzerland)
https://read.qxmd.com/read/36612135/role-of-patient-derived-models-of-cancer-in-translational-oncology
#10
REVIEW
K F Idrisova, H-U Simon, M O Gomzikova
Cancer is a heterogeneous disease. Each individual tumor is unique and characterized by structural, cellular, genetic and molecular features. Therefore, patient-derived cancer models are indispensable tools in cancer research and have been actively introduced into the healthcare system. For instance, patient-derived models provide a good reproducibility of susceptibility and resistance of cancer cells against drugs, allowing personalized therapy for patients. In this article, we review the advantages and disadvantages of the following patient-derived models of cancer: (1) PDC-patient-derived cell culture, (2) PDS-patient-derived spheroids and PDO-patient-derived organoids, (3) PDTSC-patient-derived tissue slice cultures, (4) PDX-patient-derived xenografts, humanized PDX, as well as PDXC-PDX-derived cell cultures and PDXO-PDX-derived organoids...
December 26, 2022: Cancers
https://read.qxmd.com/read/36451039/experimental-in-vitro-ex%C3%A2-vivo-and-in-vivo-models-in-prostate-cancer-research
#11
REVIEW
Verena Sailer, Gunhild von Amsberg, Stefan Duensing, Jutta Kirfel, Verena Lieb, Eric Metzger, Anne Offermann, Klaus Pantel, Roland Schuele, Helge Taubert, Sven Wach, Sven Perner, Stefan Werner, Achim Aigner
Androgen deprivation therapy has a central role in the treatment of advanced prostate cancer, often causing initial tumour remission before increasing independence from signal transduction mechanisms of the androgen receptor and then eventual disease progression. Novel treatment approaches are urgently needed, but only a fraction of promising drug candidates from the laboratory will eventually reach clinical approval, highlighting the demand for critical assessment of current preclinical models. Such models include standard, genetically modified and patient-derived cell lines, spheroid and organoid culture models, scaffold and hydrogel cultures, tissue slices, tumour xenograft models, patient-derived xenograft and circulating tumour cell eXplant models as well as transgenic and knockout mouse models...
November 30, 2022: Nature Reviews. Urology
https://read.qxmd.com/read/36358594/glioblastoma-derived-three-dimensional-ex-vivo-models-to-evaluate-effects-and-efficacy-of-tumor-treating-fields-ttfields
#12
JOURNAL ARTICLE
Vera Nickl, Ellina Schulz, Ellaine Salvador, Laureen Trautmann, Leopold Diener, Almuth F Kessler, Camelia M Monoranu, Faramarz Dehghani, Ralf-Ingo Ernestus, Mario Löhr, Carsten Hagemann
Glioblastoma (GBM) displays a wide range of inter- and intra-tumoral heterogeneity contributing to therapeutic resistance and relapse. Although Tumor Treating Fields (TTFields) are effective for the treatment of GBM, there is a lack of ex vivo models to evaluate effects on patients' tumor biology or to screen patients for treatment efficacy. Thus, we adapted patient-derived three-dimensional tissue culture models to be compatible with TTFields application to tissue culture. Patient-derived primary cells (PDPC) were seeded onto murine organotypic hippocampal slice cultures (OHSC), and microtumor development with and without TTFields at 200 kHz was observed...
October 22, 2022: Cancers
https://read.qxmd.com/read/36166004/a-novel-b7-h6-targeted-igg-like-t-cell-engaging-antibody-for-the-treatment-of-gastrointestinal-tumors
#13
JOURNAL ARTICLE
Wei Zhang, Aurélie Auguste, Xiaoyun Liao, Christian Walterskirchen, Kathrin Bauer, Yu-Hsi Lin, Ling Yang, Farzaneh Sayedian, Markus Fabits, Michael Bergmann, Carina Binder, Leticia Corrales, Anne B Vogt, Lindsey J Hudson, Martin P Barnes, Arnima Bisht, Craig Giragossian, Vladimir Voynov, Paul J Adam, Susanne Hipp
PURPOSE: Advanced-stage gastrointestinal cancers represent a high unmet need requiring new effective therapies. We investigated the antitumor activity of a novel T cell-engaging antibody (B7-H6/CD3 ITE) targeting B7-H6, a tumor-associated antigen that is expressed in gastrointestinal tumors. EXPERIMENTAL DESIGN: Membrane proteomics and IHC analysis identified B7-H6 as a tumor-associated antigen in gastrointestinal tumor tissues with no to very little expression in normal tissues...
December 1, 2022: Clinical Cancer Research
https://read.qxmd.com/read/35433436/harnessing-the-utility-of-ex-vivo-patient-prostate-tissue-slice-cultures
#14
REVIEW
Lillian M Perez, Larisa Nonn
Patient-derived prostate tissue explant cultures are powerful research tools that offer the potential for personalized medicine. These cultures preserve the local microenvironment of the surrounding stroma but are not without limitations and challenges. There are several methods and processing techniques to culture tissue ex vivo , that include explant tissue chunks and precision-cut tissue slices. Precision-cut tissue slices provide a consistent distribution of nutrients and gases to the explant. Herein we summarize the prostate tissue slice method, its limitations and discuss the utility of this model, to investigate prostate biology and therapeutic treatment responses...
2022: Frontiers in Oncology
https://read.qxmd.com/read/35402223/novel-ex-vivo-models-of-epithelial-ovarian-cancer-the-future-of-biomarker-and-therapeutic-research
#15
REVIEW
James Clark, Christina Fotopoulou, Paula Cunnea, Jonathan Krell
Epithelial ovarian cancer (EOC) is a heterogenous disease associated with variations in presentation, pathology and prognosis. Advanced EOC is typified by frequent relapse and a historical 5-year survival of less than 30% despite improvements in surgical and systemic treatment. The advent of next generation sequencing has led to notable advances in the field of personalised medicine for many cancer types. Success in achieving cure in advanced EOC has however been limited, although significant prolongation of survival has been demonstrated...
2022: Frontiers in Oncology
https://read.qxmd.com/read/35328549/perfusion-based-bioreactor-culture-and-isothermal-microcalorimetry-for-preclinical-drug-testing-with-the-carbonic-anhydrase-inhibitor-slc-0111-in-patient-derived-neuroblastoma
#16
JOURNAL ARTICLE
Zihe Huo, Remo Bilang, Claudiu T Supuran, Nicolas von der Weid, Elisabeth Bruder, Stefan Holland-Cunz, Ivan Martin, Manuele G Muraro, Stephanie J Gros
Neuroblastoma is a rare disease. Rare are also the possibilities to test new therapeutic options for neuroblastoma in clinical trials. Despite the constant need to improve therapy and outcomes for patients with advanced neuroblastoma, clinical trials currently only allow for testing few substances in even fewer patients. This increases the need to improve and advance preclinical models for neuroblastoma to preselect favorable candidates for novel therapeutics. Here we propose the use of a new patient-derived 3D slice-culture perfusion-based 3D model in combination with rapid treatment evaluation using isothermal microcalorimetry exemplified with treatment with the novel carbonic anhydrase IX and XII (CAIX/CAXII) inhibitor SLC-0111...
March 14, 2022: International Journal of Molecular Sciences
https://read.qxmd.com/read/35032716/establishing-a-standardized-method-for-the-effective-intraoperative-collection-and-biological-preservation-of-brain-tumor-tissue-samples-using-a-novel-tissue-preservation-system-a-pilot-study
#17
JOURNAL ARTICLE
Arabinda Das, Arunprasad Gunasekaran, Heather R Stephens, Joseph Mark, Scott M Lindhorst, David Cachia, Sunil J Patel, Bruce M Frankel
Glioblastoma (GB) is an aggressive tumor exhibiting extensive inter- and intratumoral heterogeneity. Several possible reasons contribute to the historical inability to develop effective therapeutic strategies for treatment of GB. One such challenge is the inability to consistently procure high quality biologically preserved specimens for use in molecular research and patient derived xenograft (PDX) model development. Currently, no scientifically derived standardized method exists for intraoperative tissue collection specifically designed with the fragility of ribonucleic acid (RNA) in mind...
January 12, 2022: World Neurosurgery
https://read.qxmd.com/read/34406120/innate-immune-activation-by-checkpoint-inhibition-in-human-patient-derived-lung-cancer-tissues
#18
JOURNAL ARTICLE
Teresa Wm Fan, Richard M Higashi, Huan Song, Saeed Daneshmandi, Angela L Mahan, Matthew S Purdom, Therese J Bocklage, Thomas A Pittman, Daheng He, Chi Wang, Andrew N Lane
Although Pembrolizumab-based immunotherapy has significantly improved lung cancer patient survival, many patients show variable efficacy and resistance development. A better understanding of the drug's action is needed to improve patient outcomes. Functional heterogeneity of the tumor microenvironment (TME) is crucial to modulating drug resistance; understanding of individual patients' TME that impacts drug response is hampered by lack of appropriate models. Lung organotypic tissue slice cultures (OTC) with patients' native TME procured from primary and brain-metastasized (BM) non-small cell lung cancer (NSCLC) patients were treated with Pembrolizumab and/or beta-glucan (WGP, an innate immune activator)...
August 18, 2021: ELife
https://read.qxmd.com/read/34251366/organotypic-slice-cultures-as-preclinical-models-of-tumor-microenvironment-in-primary-pancreatic-cancer-and-metastasis
#19
JOURNAL ARTICLE
Rüdiger Braun, Olha Lapshyna, Susanne Eckelmann, Kim Honselmann, Louisa Bolm, Meike Ten Winkel, Steffen Deichmann, Oliver Schilling, Charli Kruse, Tobias Keck, Ulrich Wellner, Peter Bronsert, Matthias Brandenburger
Realistic preclinical models of primary pancreatic cancer and metastasis are urgently needed to test the therapy response ex vivo and facilitate personalized patient treatment. However, the absence of tumor-specific microenvironment in currently used models, e.g., patient-derived cell lines and xenografts, only allows limited predictive insights. Organotypic slice cultures (OTSCs) comprise intact multicellular tissue, which can be rapidly used for the spatially resolved drug response testing. This protocol describes the generation and cultivation of viable tumor slices of pancreatic cancer and its metastasis...
June 22, 2021: Journal of Visualized Experiments: JoVE
https://read.qxmd.com/read/33975634/deconvolution-of-cell-type-specific-drug-responses-in-human-tumor-tissue-with-single-cell-rna-seq
#20
JOURNAL ARTICLE
Wenting Zhao, Athanassios Dovas, Eleonora Francesca Spinazzi, Hanna Mendes Levitin, Matei Alexandru Banu, Pavan Upadhyayula, Tejaswi Sudhakar, Tamara Marie, Marc L Otten, Michael B Sisti, Jeffrey N Bruce, Peter Canoll, Peter A Sims
BACKGROUND: Preclinical studies require models that recapitulate the cellular diversity of human tumors and provide insight into the drug sensitivities of specific cellular populations. The ideal platform would enable rapid screening of cell type-specific drug sensitivities directly in patient tumor tissue and reveal strategies to overcome intratumoral heterogeneity. METHODS: We combine multiplexed drug perturbation in acute slice culture from freshly resected tumors with single-cell RNA sequencing (scRNA-seq) to profile transcriptome-wide drug responses in individual patients...
May 11, 2021: Genome Medicine
keyword
keyword
22015
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.